We hypothesized that the inhibitory effect of IA-0130 on DSS-induced colitis symptoms and abnormal expression of inflammatory cytokines and TJ proteins may occur as a result of IA-0130 regulating the excessive activation of the IL-6 signaling pathway. Here, IL6 is linked to colitis.